LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

Search

MacroGenics Inc

Open

SectorGezondheidszorg

1.59 1.27

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.51

Max

1.61

Belangrijke statistieken

By Trading Economics

Inkomsten

-72M

-15M

Verkoop

-93M

18M

K/W

Sectorgemiddelde

38.83

56.602

EPS

-0.818

Winstmarge

-86.977

Werknemers

341

EBITDA

-71M

-12M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+184.81% upside

Dividenden

By Dow Jones

Volgende Winsten

4 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-87M

100M

Vorige openingsprijs

0.32

Vorige sluitingsprijs

1.59

Nieuwssentiment

By Acuity

50%

50%

160 / 382 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

MacroGenics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 mei 2025, 23:47 UTC

Marktinformatie

Nikkei May Trade Rangebound Amid Uncertainty Over U.S. Tariffs -- Market Talk

18 mei 2025, 23:40 UTC

Marktinformatie

Gold Rises Amid Concerns Over U.S. Fiscal Deficit -- Market Talk

18 mei 2025, 18:00 UTC

Winsten

Tax Bill News; Target, Home Depot, and Snowflake Earnings; and More Stock Market News to Watch This Week -- Barrons.com

18 mei 2025, 17:01 UTC

Top Nieuws

GM Is Fighting California on EVs. This Is What It Wants to Overturn and Why. -- Barrons.com

18 mei 2025, 16:20 UTC

Winsten

Tesla Demand Hasn't Rebounded Yet. Watch China This Week. -- Barrons.com

18 mei 2025, 12:09 UTC

Top Nieuws

Trump Sounds Upbeat on Ukraine Cease-Fire as Russia Unleashes Drone Barrage -- WSJ

17 mei 2025, 17:15 UTC

Top Nieuws

Trump Attacks Walmart for Tariff-Related Price Increases -- WSJ

17 mei 2025, 09:30 UTC

Top Nieuws
Winsten

In a Trade War, Walmart Lacks Some of Amazon's Ammunition -- Heard on the Street -- WSJ

17 mei 2025, 08:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

17 mei 2025, 08:20 UTC

Marktinformatie
Winsten

Financial Services Roundup: Market Talk

16 mei 2025, 23:18 UTC

Top Nieuws

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16 mei 2025, 22:30 UTC

Top Nieuws

U.S. Loses Last Triple-A Credit Rating -- Update

16 mei 2025, 21:56 UTC

Marktinformatie

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16 mei 2025, 21:56 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

16 mei 2025, 21:54 UTC

Top Nieuws

U.S. Loses Last Triple-A Credit Rating -- WSJ

16 mei 2025, 21:22 UTC

Marktinformatie

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16 mei 2025, 21:17 UTC

Marktinformatie

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16 mei 2025, 21:17 UTC

Top Nieuws

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16 mei 2025, 21:05 UTC

Marktinformatie

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16 mei 2025, 20:55 UTC

Acquisities, Fusies, Overnames

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 mei 2025, 20:50 UTC

Marktinformatie
Winsten

Financial Services Roundup: Market Talk

16 mei 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

16 mei 2025, 20:37 UTC

Top Nieuws

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16 mei 2025, 20:33 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16 mei 2025, 20:30 UTC

Acquisities, Fusies, Overnames

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16 mei 2025, 20:18 UTC

Top Nieuws

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16 mei 2025, 20:16 UTC

Top Nieuws

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16 mei 2025, 20:15 UTC

Winsten

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16 mei 2025, 20:11 UTC

Acquisities, Fusies, Overnames

Henry Schein: William K. Daniel Joins Board

16 mei 2025, 20:10 UTC

Acquisities, Fusies, Overnames

Henry Schein: Strategic Investment by KKR Completed

Peer Vergelijking

Prijswijziging

MacroGenics Inc Prognose

Koersdoel

By TipRanks

184.81% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4.5 USD  184.81%

Hoogste 8 USD

Laagste 2 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor MacroGenics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

7 ratings

2

Buy

5

Hold

0

Sell

Technische score

By Trading Central

1.47 / 1.64Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

160 / 382 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.